Navigation Links
Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis
Date:5/18/2009

th in Orlando, Florida.

About PX-866

PX-866 is an inhibitor of the PI-3-kinase/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer. Aberrant activation and regulation of PI-3 kinase is implicated in a large proportion of human cancers including breast, glioma, colon, ovarian, prostate and melanoma, where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). PX-866 has been shown to induce prolonged inhibition of tumor PI-3 kinase signaling following both oral and intravenous administration. The compound has been shown to have anti-tumor activity both as a single agent and in combination with other agents in a number of human tumor models. Oncothyreon initiated a Phase 1 trial of PX-866 in patients with advanced metastatic cancer in June 2008.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward-looking, including statements related to future preclinical and clinical development plans for PX PX-866. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
2. Oncothyreon files investigational new drug application for PX-866 oncology compound
3. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
4. Phase III Trial Finds Pharmaxis Bronchitol Effective
5. New nanoparticle vaccine is more effective but less expensive
6. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
7. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
8. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
9. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
10. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
11. DNA sensors found to be an effective artificial nose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a ... and products for advanced microarray diagnostics, today announced that ... the United States on the ... September 17, 2014 on the OTCQX under the symbol ... TSX Venture Exchange under its existing symbol SQD. ...
(Date:9/17/2014)... California , 17 de septiembre de ... ("la compañía"), principal proveedor mundial de soluciones ... las ciencias de la vida, anunció hoy ... de logística global con sede en Rótterdam, ... base de clientes Europa en rápido crecimiento. ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... Inc., (TSX: IXS.V; OTC Bulletin Board: IXSBF),( http://www.ixsbio.com ... of monoclonal antibodies based on its Dynamic Cross ... a large scale,primate study of DXL625 (CD20), the ... study in cynomolgus monkeys of DXL625, an antibody,directed ...
... Odyssey Thera, Inc. announced,that it has received a ... progress a discovery stage drug candidate into,pre-clinical development. ... as part of the ongoing collaboration with Pfizer., ... of the collaboration with,Pfizer," said John K. Westwick, ...
... (OTC,Pink Sheets: AIMM) today reported a net loss of $86,000, ... ended June 30, 2008, compared with,a net loss of $62,000, ... months ended June 30, 2007. For the six months ended ... share basic and diluted, compared,with net loss of $54,000, or ...
Cached Biology Technology:InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 3
(Date:9/17/2014)... affordable health care to reproductive technologies, the justice ... ability of people to identify key issues, articulate ... and find the most defensible ways forward. But ... these societal conversations?, The Hastings Center and the ... have teamed up to publish a series of ...
(Date:9/17/2014)... UT Arlington engineering professor and his doctoral student have ... can accumulate water collected from fog and dew., The ... world or deserts around the globe., Cheng Luo, professor ... Heng, PhD candidate in the same College of Engineering ... 25 edition of ACS, (American Chemical Society) ...
(Date:9/17/2014)... has developed, very cleverly, some lessons on how to ... said Joseph Shaw, director of the Optical Technology Center ... structures at the nanoscale, we,ll discover them." , Some ... August during a conference called "The Nature of Light: ... of the University of Arizona College of Optical Sciences. ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3Shorebird's beak inspires UT Arlington research on water collection 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3
... may not be the answer to mitigating climate change by ... to an international team of plant biologists. The researchers found ... fungi (AMF) -- a type of fungus that is often ... then leads to higher decomposition rates of organic materials, said ...
... the methane on Earth comes from the ocean,s oxygen-rich waters, ... this potent greenhouse gas. Now researchers report that they have ... the most abundant microbes on the planet. The findings ... who made the discovery did not set out to explain ...
... part of the marine ecosystem, fostering biodiversity and protecting ... with pollution and harmful fishing practices, are one of ... One of the solutions to the crisis ... Tel Aviv University,s Department of Molecular Microbiology and Biotechnology, ...
Cached Biology News:Plants' fungi allies may not help store climate change's extra carbon 2Study identifies prime source of ocean methane 2Study identifies prime source of ocean methane 3Viruses could be the key to healthy corals 2
... a simple high performance method for removing ... without significant dilution of protein solution. ... Detergent-OUT Spin column and collect detergent free ... removing detergent from a maximum of 0.2 ...
... Chemicon Detergent-OUT SDS Kit is a simple ... protein solutions. Removes detergents without significant ... the protein solution on the Detergent-OUT Spin ... Med columns are suitable for removing ...
... from frozen embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 7 microns ... large (3-5 mm in diameter) in comparison ...
... Zyagen tissue microarrays are derived from frozen ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... coated slides. Sections are large (3-5mm in ...
Biology Products: